Post-Conference Perspectives: Managing R/R B-ALL with CAR T-Cell Therapy - Episode 5
Outcomes Data Following Brexucabtagene Autoleucel Therapy in Patients With R/R B-ALL
Jae Park, MD, explains how real-world CAR T-cell therapy data in patients with relapsed/refractory B-cell acute lymphoblastic leukemia shows high response rates but emphasizes the ongoing need for optimizing toxicity management, with trends toward earlier treatment and cell collection.
